293 related articles for article (PubMed ID: 14623524)
1. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Dixon JM; Jackson J; Renshaw L; Miller WR
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):295-9. PubMed ID: 14623524
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
4. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Dixon JM; Love CD; Renshaw L; Bellamy C; Cameron DA; Miller WR; Leonard RC
Endocr Relat Cancer; 1999 Jun; 6(2):227-30. PubMed ID: 10731113
[TBL] [Abstract][Full Text] [Related]
5. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Miller WR; Dixon JM; Cameron DA; Anderson TJ
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):103-7. PubMed ID: 11850213
[TBL] [Abstract][Full Text] [Related]
6. Should aromatase inhibitors replace tamoxifen?
Drug Ther Bull; 2003 Aug; 41(8):57-9. PubMed ID: 12966738
[TBL] [Abstract][Full Text] [Related]
7. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
Smith IE
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):289-93. PubMed ID: 14623523
[TBL] [Abstract][Full Text] [Related]
8. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
[TBL] [Abstract][Full Text] [Related]
10. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
Murray J; Young OE; Renshaw L; White S; Williams L; Evans DB; Thomas JS; Dowsett M; Dixon JM
Breast Cancer Res Treat; 2009 Apr; 114(3):495-501. PubMed ID: 18438705
[TBL] [Abstract][Full Text] [Related]
11. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
Ellis MJ; Coop A; Singh B; Tao Y; Llombart-Cussac A; Jänicke F; Mauriac L; Quebe-Fehling E; Chaudri-Ross HA; Evans DB; Miller WR
Cancer Res; 2003 Oct; 63(19):6523-31. PubMed ID: 14559846
[TBL] [Abstract][Full Text] [Related]
12. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
14. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Sainsbury R
Br J Cancer; 2004 May; 90(9):1733-9. PubMed ID: 15150604
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.
Dixon JM; Anderson TJ; Miller WR
Eur J Cancer; 2002 Nov; 38(17):2214-21. PubMed ID: 12441257
[TBL] [Abstract][Full Text] [Related]
17. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
[TBL] [Abstract][Full Text] [Related]
18. Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.
Kurosumi M; Takatsuka Y; Watanabe T; Imoto S; Inaji H; Tsuda H; Akiyama F; Sakamoto G; Ikeda T; Noguchi S
J Cancer Res Clin Oncol; 2008 Jun; 134(6):715-22. PubMed ID: 18075758
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors in early breast cancer treatment.
Mauriac L; Smith I
Semin Oncol; 2003 Aug; 30(4 Suppl 14):46-57. PubMed ID: 14513436
[TBL] [Abstract][Full Text] [Related]
20. Role of aromatase inhibitors in the treatment of breast cancer.
Choueiri TK; Alemany CA; Abou-Jawde RM; Budd GT
Clin Ther; 2004 Aug; 26(8):1199-214. PubMed ID: 15476902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
